Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 1.2 % | Antihyperglycemic activity in STZ-induced diabetic Sprague-Dawley rat assessed as decrease in blood glucose at 100 mg/kg, po after 180 mins relative to control | ChEMBL. | 17336063 |
Activity (functional) | = 1.3 % | Antihyperglycemic activity in STZ-induced diabetic Sprague-Dawley rat assessed as decrease in blood glucose at 100 mg/kg, po after 240 mins relative to control | ChEMBL. | 17336063 |
Activity (functional) | = 5.52 % | Antihyperglycemic activity in STZ-induced diabetic Sprague-Dawley rat assessed as decrease in blood glucose at 100 mg/kg, po after 5 hrs relative to control | ChEMBL. | 17336063 |
Activity (functional) | = 6.3 % | Antihyperglycemic activity in STZ-induced diabetic Sprague-Dawley rat assessed as decrease in blood glucose at 100 mg/kg, po after 90 mins relative to control | ChEMBL. | 17336063 |
Activity (functional) | = 8.5 % | Antihyperglycemic activity in STZ-induced diabetic Sprague-Dawley rat assessed as decrease in blood glucose at 100 mg/kg, po after 30 mins relative to control | ChEMBL. | 17336063 |
Activity (functional) | = 8.9 % | Antihyperglycemic activity in STZ-induced diabetic Sprague-Dawley rat assessed as decrease in blood glucose at 100 mg/kg, po after 120 mins relative to control | ChEMBL. | 17336063 |
Activity (functional) | = 9.6 % | Antihyperglycemic activity in STZ-induced diabetic Sprague-Dawley rat assessed as decrease in blood glucose at 100 mg/kg, po after 60 mins relative to control | ChEMBL. | 17336063 |
Activity (functional) | = 19.3 % | Antihyperglycemic activity in STZ-induced diabetic Sprague-Dawley rat assessed as decrease in blood glucose at 100 mg/kg, po after 24 hrs relative to control | ChEMBL. | 17336063 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.